Last reviewed · How we verify
Icodextrin Peritoneal Dialysis Solution
Icodextrin is a glucose polymer that acts as an osmotic agent in peritoneal dialysis solution to draw excess fluid from the blood across the peritoneal membrane.
Icodextrin is a glucose polymer that acts as an osmotic agent in peritoneal dialysis solution to enhance ultrafiltration and remove excess fluid from the peritoneal cavity. Used for Peritoneal dialysis in patients with end-stage renal disease requiring enhanced ultrafiltration.
At a glance
| Generic name | Icodextrin Peritoneal Dialysis Solution |
|---|---|
| Also known as | Extraneal |
| Sponsor | RenJi Hospital |
| Drug class | Osmotic agent for peritoneal dialysis |
| Modality | Small molecule |
| Therapeutic area | Nephrology / Renal replacement therapy |
| Phase | FDA-approved |
Mechanism of action
Icodextrin functions as a colloid osmotic agent with a high molecular weight that cannot easily cross the peritoneal membrane, creating an osmotic gradient that drives ultrafiltration of excess fluid during peritoneal dialysis. Unlike glucose-based dialysates, icodextrin provides sustained ultrafiltration over longer dwell times and reduces glucose absorption, making it particularly useful for overnight or long-dwell exchanges in peritoneal dialysis patients.
Approved indications
- Peritoneal dialysis in end-stage renal disease patients requiring fluid removal
Common side effects
- Peritonitis
- Abdominal pain
- Hyperamylasemia
- Allergic reactions
Key clinical trials
- Efficacy and Safety of XyloCore Peritoneal Dialysis Solution. (PHASE3)
- Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients
- Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients (PHASE4)
- Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine (PHASE2)
- Pharmacokinetics of Single- and Double-dose Icodextrin (NA)
- Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis (PHASE4)
- Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients (PHASE1)
- Incremental PD With Single Icodextrin Exchange (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Icodextrin Peritoneal Dialysis Solution CI brief — competitive landscape report
- Icodextrin Peritoneal Dialysis Solution updates RSS · CI watch RSS
- RenJi Hospital portfolio CI